GLP-1 Drugs Significantly Reduce Asthma Attacks in People With Diabetes
Diabetes patients prescribed GLP-1 receptor agonists had 2-3 times fewer asthma exacerbations compared to those on other diabetes drugs, suggesting GLP-1 drugs may directly benefit airway inflammation.
Quick Facts
What This Study Found
GLP-1RA users had significantly fewer asthma exacerbations at 6 months compared to SGLT-2 inhibitors (IRR 2.98), DPP-4 inhibitors (IRR 2.45), sulfonylureas (IRR 1.83), and basal insulin (IRR 2.58), all with p<0.05.
Key Numbers
448 GLP-1RA; IRR vs GLP-1RA: SGLT2i 2.98, DPP-4i 2.45, SU 1.83, insulin 2.58; asthma symptom visits also lower with GLP-1RA
How They Did This
Retrospective cohort study using electronic health records (2000-2018). New users of GLP-1RA (n=448) compared to SGLT-2i (n=112), DPP-4i (n=435), sulfonylureas (n=2,253), and basal insulin (n=2,692). Propensity score adjustment. Zero-inflated Poisson regression with multiple covariates.
Why This Research Matters
Asthma affects 300+ million people globally, and those with metabolic conditions often have worse outcomes. GLP-1 drugs could provide dual benefit — treating diabetes while also reducing airway inflammation and asthma attacks.
The Bigger Picture
GLP-1 drugs continue to reveal benefits beyond glucose control. Anti-inflammatory effects in the lungs add to their cardiovascular, renal, and neurological benefits, positioning them as potential multi-organ protective therapies.
What This Study Doesn't Tell Us
Retrospective observational study — cannot prove causation. Potential unmeasured confounders. GLP-1RA users may be healthier at baseline despite propensity score adjustment. Single academic healthcare system. Short 6-month follow-up.
Questions This Raises
- ?Would GLP-1 agonists reduce asthma attacks in people without diabetes?
- ?Which specific GLP-1 drug provides the greatest asthma benefit?
- ?Is the asthma benefit due to anti-inflammatory effects, weight loss, or both?
Trust & Context
- Key Stat:
- 2-3x fewer asthma attacks GLP-1RA users had 2-3 times fewer asthma exacerbations at 6 months compared to patients on all other diabetes drug classes
- Evidence Grade:
- Moderate evidence: large retrospective cohort with propensity score adjustment and consistent results across all comparators, but observational design cannot establish causation.
- Study Age:
- Published 2021. Prospective clinical trials investigating GLP-1 drugs specifically for asthma may be underway.
- Original Title:
- Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
- Published In:
- American journal of respiratory and critical care medicine, 203(7), 831-840 (2021)
- Authors:
- Foer, Dinah, Beeler, Patrick E, Cui, Jing, Karlson, Elizabeth W, Bates, David W, Cahill, Katherine N
- Database ID:
- RPEP-05386
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs like Ozempic help with asthma?
This study suggests they can. Diabetes patients who started GLP-1 drugs had significantly fewer asthma attacks compared to those on other diabetes medications. The mechanism may involve anti-inflammatory effects on airway tissue, though this needs confirmation in clinical trials.
Should I switch my diabetes medication if I have asthma?
Discuss this with your doctor. If you have both type 2 diabetes and asthma, a GLP-1 drug might provide dual benefit. However, this was an observational study and medication changes should be made based on your complete medical profile.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05386APA
Foer, Dinah; Beeler, Patrick E; Cui, Jing; Karlson, Elizabeth W; Bates, David W; Cahill, Katherine N. (2021). Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.. American journal of respiratory and critical care medicine, 203(7), 831-840. https://doi.org/10.1164/rccm.202004-0993OC
MLA
Foer, Dinah, et al. "Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.." American journal of respiratory and critical care medicine, 2021. https://doi.org/10.1164/rccm.202004-0993OC
RethinkPeptides
RethinkPeptides Research Database. "Asthma Exacerbations in Patients with Type 2 Diabetes and As..." RPEP-05386. Retrieved from https://rethinkpeptides.com/research/foer-2021-asthma-exacerbations-in-patients
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.